Key takeaways
- 15,000–25,000 US high-risk IgAN patients (UPCR >1g/g, declining eGFR, already optimised on ACEi/ARB±SGLT2i) — the near-term addressable market
- 5,000–8,000 US IgAN patients currently on novel therapy (budesonide or sparsentan) — ~10-15% penetration of the biopsy-confirmed population
- 41% ESRD-composite reduction with SGLT2i in the IgAN subgroup (DAPA-CKD) — raising the treatment bar before a novel agent is considered
- $60K–70K vs $100K–175K Budesonide WAC vs ICER's modelled cost/QALY range — a new entrant with eGFR-confirmed (not accelerated) approval has the stronger value position
The binding constraint: eGFR-confirmed evidence, not UPCR surrogate data, is what resolves the payer caution both accelerated-approval incumbents currently face.
Budesonide (Tarpeyo, ~60% IgAN-specific share) and sparsentan (Filspari) are both marketed under FDA accelerated approval based on the UPCR proteinuria surrogate, with confirmatory eGFR-outcome data still pending (NefIgArd Part B; PROTECT 2-year). Of an estimated 150,000 US IgAN patients (70,000-90,000 biopsy-confirmed), only 5,000-8,000 are on novel therapy today — a low penetration rate driven in part by payer caution around accelerated-approval status: several major payers have already tightened UPCR thresholds beyond the FDA label pending confirmatory data, and some have signalled non-coverage risk if confirmatory trials disappoint.
The addressable near-term market is not the full IgAN population but the high-risk cohort — an estimated 15,000-25,000 US patients with UPCR >1g/g and declining eGFR who have already been optimised on ACEi/ARB and, increasingly, SGLT2i (DAPA-CKD's IgAN subgroup showed a 41% ESRD-composite reduction). Nephrology KOLs have moved past UPCR as the practice endpoint; eGFR slope is what predicts ESRD prevention and what the specialist community actually uses to judge a drug (NefIgArd: +3.87 mL/min/year; PROTECT: -2.0 vs -4.7 mL/min/year at 2 years).
For a pre-launch entrant, a standard FDA approval built on confirmed eGFR-slope data, rather than a second accelerated approval on UPCR alone, is the single clearest way to differentiate on payer terms from day one, sidestepping the confirmatory-data overhang both incumbents carry. ICER has flagged IgAN for a 2024-2025 pre-assessment; at budesonide's ~$60,000-70,000/year WAC, the cost/QALY model sits near the $100,000-175,000 threshold depending on how eGFR benefit translates to ESRD delay — a new entrant pricing at parity with eGFR-confirmed data would have a materially stronger ICER position. Pre-launch priorities: engage nephrology KOLs now on eGFR-slope evidence, model the UPCR-to-eGFR bridge for payer medical directors, and begin Part D PBM contracting and proactive ICER dialogue 18-24 months ahead of launch.
Current IgAN standard of care — US, 2024
| Drug (Brand / INN) | Mechanism | US Share | WAC | Approval Basis | Payer Posture |
|---|---|---|---|---|---|
| Tarpeyo (budesonide) | Oral targeted glucocorticoid | ~60% IgAN-specific share | ~$60,000-70,000/yr WAC | Accelerated approval (UPCR surrogate) | Confirmatory NefIgArd Part B pending; payer caution on UPCR thresholds |
| Filspari (sparsentan) | Oral dual ET/AT antagonist | Building share | ~$80,000-100,000/yr WAC | Accelerated approval (UPCR -49.8%) | Confirmatory PROTECT 2-yr eGFR data pending |
| Iptacopan (pipeline) | Oral complement Factor B inhibitor | Pre-approval | Not yet set | Phase 3 APPLAUSE-IgAN primary endpoint met; FDA submission 2024 | Not yet established; mechanism-matched evidence expected by KOLs |
Sources: IQVIA IgAN market data 2024; IQVIA IgAN claims database analysis 2023; Coon JT et al. Kidney Int 2022; Barratt J et al. NEJM 2023 (NefIgArd); Heerspink HJL et al. NEJM 2023 (PROTECT); Wheeler DC et al. NEJM 2022 (DAPA-CKD IgAN subgroup); APPLAUSE-IgAN ClinicalTrials.gov results 2024; UHC IgAN PA criteria 2024; ICER 2025 assessment pipeline.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Would a standard FDA approval built on eGFR-slope data outperform a second accelerated approval on UPCR surrogate data commercially, given the payer caution both incumbents face? • Confirmatory-trial status and payer restriction analysis for budesonide/sparsentan • eGFR-slope vs UPCR endpoint framing for FDA and payer audiences • standard-approval commercial advantage case
- How large is the high-risk, treatment-eligible IgAN cohort once ACEi/ARB and SGLT2i optimisation are accounted for, and how should it be sized pre-launch? • High-risk cohort sizing (15,000-25,000 patients) • SGLT2i-optimisation impact on the addressable population • nephrology KOL prescribing-decision framework
- What PA criteria and value benchmark should a new IgAN entrant plan for, and how does eGFR-confirmed data change that position? • PA criteria precedent (biopsy + UPCR threshold + ACEi/ARB step) • ICER 2024-2025 pre-assessment cost/QALY modelling • PBM Part D contracting timeline
What's inside
-
1 · The Binding Constraint 2 pp
- eGFR-confirmed evidence vs accelerated-approval UPCR-surrogate risk
- Pressure-tested against payer caution already visible on both incumbents
-
2 · Standard-of-Care Landscape & Entrenchment 5 pp
- Budesonide and sparsentan's accelerated-approval share and confirmatory-trial overhang
- Nephrology KOL shift from UPCR to eGFR slope as the practice endpoint
- Pipeline crowding (iptacopan, atacicept, sibeprenlimab) and mechanism-matched evidence expectations
-
3 · Target Population & Unmet Need 5 pp
- High-risk treatment-eligible cohort sizing (15,000-25,000 patients)
- SGLT2i optimisation raising the bar before novel-agent consideration
- Biopsy-confirmation gate constraining addressable market size
-
4 · Anticipated Payer & Access Posture 5 pp
- PA criteria forming around UPCR thresholds and ACEi/ARB step-edit
- ICER 2024-2025 pre-assessment cost/QALY modelling
- Part D PBM contracting and proactive ICER engagement timeline
-
5 · The Assumption Register 2 pp
- Every population, share, and pricing figure sourced and confidence-rated
- Built to survive an internal challenge meeting
-
6 · KOL & Centre Readiness 3 pp
- 100-150 US glomerulonephritis nephrology KOLs at academic centres
- ASN and NephCure as professional/patient engagement channels
- Pre-launch engagement sequencing
-
7 · Client Alignment Questions 2 pp
- Open decisions on approval pathway strategy and pricing tier
- Structured for an advisory board or internal alignment session
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx delivers IgA nephropathy launch-readiness intelligence built for pre-launch commercial, medical affairs, and market access teams. Custom assessment in 72 hours.
- 1. Submit your requestUse the intake form to specify your asset, target population, and pre-launch question.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and access-architecture assumptions.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment synthesises three independent research angles into one integrated pre-launch view: competitive positioning, target-population epidemiology, and anticipated payer posture. Every figure is drawn from the named primary source in the underlying research base and cross-checked before inclusion; no figure is carried from model memory.
IgAN launch-readiness sources: IQVIA IgAN market data 2024 and claims database analysis 2023; Coon JT et al., Kidney Int 2022 (US IgAN prevalence); Barratt J et al., NEJM 2023 (NefIgArd); Heerspink HJL et al., NEJM 2023 (PROTECT); Wheeler DC et al., NEJM 2022 (DAPA-CKD IgAN subgroup); KDIGO IgAN 2021 with SGLT2i addendum; APPLAUSE-IgAN ClinicalTrials.gov results 2024; Vera Therapeutics ORIGIN trial; GSK sibeprenlimab Phase 3; UHC/Cigna IgAN PA criteria 2024; ICER 2024-2025 assessment pipeline; ASN membership IgAN subspecialist list; NephCure IgAN prescriber database.
- Drug approval dates and mechanism claims verified against FDA approval records referenced in the source research base
- Clinical trial results (NefIgArd, PROTECT, DAPA-CKD, APPLAUSE-IgAN) verified against the named primary publications in the source research base
- Payer PA-criteria and ICER pre-assessment scope cross-checked against named payer and ICER sources in the source research base
- Anticipated payer posture is explicitly flagged as anticipated, not confirmed policy, and separated from verified clinical/regulatory facts
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned Launch Readiness assessment includes a 24-30 page PDF covering the binding constraint, SoC entrenchment, target-population sizing, and anticipated payer posture; an editable Excel population-sizing and access-scenario model; and a 12-15 slide PowerPoint readout. A 45-minute analyst call is included with delivery.
Sources How are figures verified for a pre-launch assessment?
Every figure is cited to a live source at the point of writing and cross-checked in an independent audit pass: prescription and claims data, the published US prevalence literature, and the primary proteinuria-endpoint trial publications. Anticipated payer posture is explicitly distinguished from confirmed policy throughout.
Customisation Can I tailor scope to my specific asset or target population?
Yes. The intake form captures your asset's mechanism, target patient segment, and the specific pre-launch question you need answered — a scoping call confirms comparators and access-architecture assumptions before research begins.